Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.49) by 2.04 percent. This is a 50 percent increase over losses of $(1.00) per share from the same period last year.
Air Products Outlook: FY23 Adj. EPS $11.30 – $11.50 Vs. $11.38 Estimate, Q3 Adj. EPS $2.85 – $2.95 Vs. $2.93 Estimate
It is not possible, without unreasonable efforts, to identify the timing or occurrence of similar future events or the potential for other transactions that may impact future GAAP EPS. Furthermore, it is not possible to
